{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:29:21Z","timestamp":1760984961256},"reference-count":60,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.canlet.2014.03.030","type":"journal-article","created":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T15:01:45Z","timestamp":1396450905000},"page":"26-34","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["The NF-\u03baB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma"],"prefix":"10.1016","volume":"349","author":[{"given":"Marta","family":"Celegato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cinzia","family":"Borghese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naike","family":"Casagrande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Colombatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonino","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Aldinucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2014.03.030_b0005","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/asheducation-2009.1.507","article-title":"Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma. Hematology","author":"Younes","year":"2009","journal-title":"Am. Soc. Hematol. Ed. Program."},{"issue":"5","key":"10.1016\/j.canlet.2014.03.030_b0010","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12185-012-1199-2","article-title":"Advances in the treatment of Hodgkin lymphoma","volume":"96","author":"Eichenauer","year":"2012","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canlet.2014.03.030_b0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/asheducation-2013.1.394","article-title":"Novel therapy for Hodgkin lymphoma. Hematology","volume":"2013","author":"Batlevi","year":"2013","journal-title":"Am. Soc. Hematol. Ed. Program."},{"issue":"8","key":"10.1016\/j.canlet.2014.03.030_b0020","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","article-title":"Crosstalk in NF-kappaB signaling pathways","volume":"12","author":"Oeckinghaus","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2014.03.030_b0025","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"Kuppers","year":"2012","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.canlet.2014.03.030_b0030","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1084\/jem.20090528","article-title":"TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma","volume":"206","author":"Schmitz","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2014.03.030_b0035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin\u2019s lymphoma","volume":"9","author":"Kuppers","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2014.03.030_b0040","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1038\/sj.onc.1205337","article-title":"Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells","volume":"21","author":"Horie","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2014.03.030_b0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3727\/096504012X13285365944292","article-title":"Targeted repression of overexpressed CD30 downregulates NF-kappaB and ERK1\/2 pathway in Hodgkin lymphoma cell lines","volume":"19","author":"Watanabe","year":"2011","journal-title":"Oncol. Res."},{"issue":"4","key":"10.1016\/j.canlet.2014.03.030_b0050","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2011.265","article-title":"Notch is an essential upstream regulator of NF-kappaB and is relevant for survival of Hodgkin and Reed-Sternberg cells","volume":"26","author":"Schwarzer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.03.030_b0055","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V85.3.780.bloodjournal853780","article-title":"Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin\u2019s disease cell lines","volume":"85","author":"Carbone","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0060","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/10428194.2011.605190","article-title":"The role of CD40\/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment","volume":"53","author":"Aldinucci","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.canlet.2014.03.030_b0065","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2141.2001.02977.x","article-title":"Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin\u2019s disease","volume":"114","author":"Molin","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2014.03.030_b0070","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1182\/blood.V88.9.3299.bloodjournal8893299","article-title":"Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin\u2019s disease cell line","volume":"88","author":"Pinto","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0075","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/ijc.23119","article-title":"Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5\/Rantes in tumor cell growth and microenvironmental interactions","volume":"122","author":"Aldinucci","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.03.030_b0080","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin\u2019s lymphoma","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.canlet.2014.03.030_b0085","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/ajh.23361","article-title":"Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma","volume":"88","author":"Sauer","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2014.03.030_b0090","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/path.2711","article-title":"The classical Hodgkin\u2019s lymphoma microenvironment and its role in promoting tumour growth and immune escape","volume":"221","author":"Aldinucci","year":"2010","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2014.03.030_b0095","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-2141.2009.07945.x","article-title":"IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma","volume":"148","author":"Aldinucci","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2014.03.030_b0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2141.2010.08497.x","article-title":"IRF4 silencing inhibits Hodgkin lymphoma cell proliferation, survival and CCL5 secretion","volume":"152","author":"Aldinucci","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2014.03.030_b0105","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ni1357","article-title":"Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination","volume":"7","author":"Klein","year":"2006","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2014.03.030_b0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/PAI.0b013e3181cf1126","article-title":"MUM1\/IRF4: a review","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.canlet.2014.03.030_b0115","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood.V95.6.2084","article-title":"A monoclonal antibody (MUM1p) detects expression of the MUM1\/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells","volume":"95","author":"Falini","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0120","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1046\/j.1365-2141.2002.03456.x","article-title":"Expression pattern of MUM1\/IRF4 in the spectrum of pathology of Hodgkin\u2019s disease","volume":"117","author":"Carbone","year":"2002","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.canlet.2014.03.030_b0125","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/10428194.2013.800196","article-title":"Bortezomib down-modulates the survival factor interferon regulatory factor 4 in Hodgkin lymphoma cell lines and decreases the protective activity of Hodgkin lymphoma-associated fibroblasts","volume":"55","author":"Celegato","year":"2014","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2014.03.030_b0130","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1111\/j.1349-7006.2010.01693.x","article-title":"The side population, as a precursor of Hodgkin and Reed-Sternberg cells and a target for nuclear factor-kappaB inhibitors in Hodgkin\u2019s lymphoma","volume":"101","author":"Nakashima","year":"2010","journal-title":"Cancer Sci."},{"issue":"18","key":"10.1016\/j.canlet.2014.03.030_b0135","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood-2012-01-405951","article-title":"Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival","volume":"120","author":"Ranuncolo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0140","first-page":"245","article-title":"Inhibition of NF-kappaB signaling as a strategy in disease therapy","volume":"349","author":"Gilmore","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.canlet.2014.03.030_b0145","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0960-894X(00)00114-1","article-title":"Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C","volume":"10","author":"Matsumoto","year":"2000","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.canlet.2014.03.030_b0150","doi-asserted-by":"crossref","first-page":"24625","DOI":"10.1074\/jbc.M112063200","article-title":"Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin","volume":"277","author":"Ariga","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.canlet.2014.03.030_b0155","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.4049\/jimmunol.1300155","article-title":"Pleiotropic Potential of Dehydroxymethylepoxyquinomicin for NF-kappaB suppression via reactive oxygen species and unfolded protein response","volume":"190","author":"Nakajima","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2014.03.030_b0160","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0165","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/labinvest.3700528","article-title":"IkappaBalpha independent induction of NF-kappaB and its inhibition by DHMEQ in Hodgkin\/Reed-Sternberg cells","volume":"87","author":"Watanabe","year":"2007","journal-title":"Lab Invest"},{"key":"10.1016\/j.canlet.2014.03.030_b0170","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1080\/10428190410001683633","article-title":"Interactions between tissue fibroblasts in lymph nodes and Hodgkin\/Reed-Sternberg cells","volume":"45","author":"Aldinucci","year":"2004","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.canlet.2014.03.030_b0175","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/ijc.24389","article-title":"Functional coexpression of Interleukin (IL)-7 and its receptor (IL-7R) on Hodgkin and Reed-Sternberg cells: Involvement of IL-7 in tumor cell growth and microenvironmental interactions of Hodgkin\u2019s lymphoma","volume":"125","author":"Cattaruzza","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.03.030_b0180","doi-asserted-by":"crossref","first-page":"7061","DOI":"10.1016\/j.tet.2004.01.103","article-title":"Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-kB inhibitor","volume":"60","author":"Suzuki","year":"2004","journal-title":"Tetrahedron"},{"key":"10.1016\/j.canlet.2014.03.030_b0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10428199309148499","article-title":"Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines","volume":"9","author":"Drexler","year":"1993","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2014.03.030_b0190","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood.V87.8.3418.bloodjournal8783418","article-title":"Peripheral blood mononuclear cells of a patient with advanced Hodgkin\u2019s lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells","volume":"87","author":"Wolf","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzyme Regul."},{"issue":"9","key":"10.1016\/j.canlet.2014.03.030_b0200","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V97.9.2798","article-title":"Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin\/Reed-Sternberg cells","volume":"97","author":"Hinz","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2009.230","article-title":"TNF-alpha-converting enzyme (TACE\/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species","volume":"24","author":"Vahdat","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2014.03.030_b0210","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/1078-0432.CCR-03-0494","article-title":"Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors","volume":"10","author":"Zheng","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2014.03.030_b0215","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/1042819031000067558","article-title":"Nuclear transcription factor-kappaB in Hodgkin\u2019s disease","volume":"44","author":"Younes","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2014.03.030_b0220","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-065X.2012.01099.x","article-title":"NF-kappaB and the link between inflammation and cancer","volume":"246","author":"DiDonato","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.canlet.2014.03.030_b0225","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-kappaB in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol. Rev."},{"issue":"15","key":"10.1016\/j.canlet.2014.03.030_b0230","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1039\/c2ob07104e","article-title":"Involvement of DNA binding domain in the cellular stability and importin affinity of NF-kappaB component RelB","volume":"10","author":"Takeiri","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.canlet.2014.03.030_b0235","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0002-9440(10)64878-X","article-title":"Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells","volume":"160","author":"Aldinucci","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2014.03.030_b0240","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1182\/blood-2002-11-3507","article-title":"MEK\/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival","volume":"102","author":"Zheng","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2014.03.030_b0245","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ajpath.2011.10.007","article-title":"Ets-1 activates overexpression of JunB and CD30 in Hodgkin\u2019s lymphoma and anaplastic large-cell lymphoma","volume":"180","author":"Watanabe","year":"2012","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2014.03.030_b0250","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1046\/j.1365-2249.2001.01453.x","article-title":"Thiols decrease cytokine levels and down-regulate the expression of CD30 on human allergen-specific T helper (Th) 0 and Th2 cells","volume":"123","author":"Bengtsson","year":"2001","journal-title":"Clin. Exp. Immunol."},{"issue":"120(3)","key":"10.1016\/j.canlet.2014.03.030_b0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/blood-2011-12-397893","article-title":"Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation","volume":"19","author":"Gopal","year":"2012","journal-title":"Blood"},{"issue":"30(18)","key":"10.1016\/j.canlet.2014.03.030_b0260","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"20","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.canlet.2014.03.030_b0265","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/S1470-2045(13)70501-1","article-title":"Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin\u2019s lymphoma: a phase 1, open-label, dose-escalation study","volume":"14","author":"Younes","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2014.03.030_b0270","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1349-7006.2007.00687.x","article-title":"Expression of CCL17 and CCL22 by latent membrane protein 1-positive tumor cells in age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorder","volume":"99","author":"Takegawa","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2014.03.030_b0275","doi-asserted-by":"crossref","first-page":"27199","DOI":"10.1074\/jbc.M403107200","article-title":"Transcriptional mechanisms regulating alveolar epithelial cell-specific CCL5 secretion in pulmonary tuberculosis","volume":"279","author":"Wickremasinghe","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2014.03.030_b0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ijc.11370","article-title":"Expression of CCL5\/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue","volume":"107","author":"Fischer","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2014.03.030_b0285","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/gm240","article-title":"Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances","volume":"3","author":"Derenzini","year":"2011","journal-title":"Genome Med."},{"issue":"5","key":"10.1016\/j.canlet.2014.03.030_b0290","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/sj.leu.2403716","article-title":"HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3","volume":"19","author":"Nagel","year":"2005","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.canlet.2014.03.030_b0295","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.leu.2402799","article-title":"False leukemia-lymphoma cell lines: an update on over 500 cell lines","volume":"17","author":"Drexler","year":"2003","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.canlet.2014.03.030_b0300","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/blood-2011-10-386763","article-title":"PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma","volume":"119","author":"Meadows","year":"2012","journal-title":"Blood"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514001992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383514001992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T04:36:28Z","timestamp":1597638988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383514001992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0304383514001992"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2014.03.030","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The NF-\u03baB inhibitor DHMEQ decreases survival factors, overcomes the protective activity of microenvironment and synergizes with chemotherapy agents in classical Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2014.03.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}